We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously...
WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition PR Newswire NEW YORK, Jan. 24, 2018 NEW YORK, Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
By Jonathan D. Rockoff This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (January 23...
By Jonathan D. Rockoff Big drugmakers, searching for new sources of revenue, are paying hefty premiums for biotechnology businesses, with two multibillion-dollar acquisitions announced Monday...
By Jonathan D. Rockoff A pair of multibillion-dollar biotech deals announced Monday commanded hefty premiums, driven by big drugmakers' need for new sources of revenue amid a scarcity of...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc. PR Newswire NEW YORK, Jan. 22, 2018 NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law PLLC is...
By Cara Lombardo Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgene's portfolio of...
Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc. PR Newswire SAN DIEGO, Jan. 22, 2018 SAN DIEGO, Jan. 22, 2018 /PRNewswire/...
By Cara Lombardo Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgene's portfolio of...
By Cara Lombardo Celgene Corp. (CELG) on Monday said it agreed to buy Juno Therapeutics Inc. (JUNO) for $87 a share in cash, or about $9 billion, in a move that will bolster Celgene's...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions